Diagnostic decisions based solely on these PSA indicators may lead to excessive interventions; therefore, an optimal approach should consider a broader clinical context to minimize the risk of unnecessary biopsies and improve the accuracy of prostate cancer diagnosis. The gene discussed is PROS1; the disease is prostate carcinoma.